MOVANTIK
(https://movantik.com) 📸 Data Snapshot: May 24, 2026Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
There is virtually zero semantic drift between the homepage signal and sub-page substance. The homepage H1 ‘MOVANTIK gets you moving’ is a consumer-facing promise that is directly supported by the About page’s technical breakdown of ‘Rapid response’ and the clinical confirmation of effectiveness in adults with non-cancer pain. The messaging remains consistent across the HCP and patient-facing pages, focusing on the prevalence of OIC and the specific mechanism of naloxegol.
Semantic Coherence is read from the heading hierarchy first: what each page announces in its H1 and headings, then whether the body actually delivers on it. Below is the structure the engine mapped, followed by the clean text to check for drift between promise and reality.
🏗️ Semantic Structure — heading hierarchy & page identity (the promise the page makes)
HOMEPAGE (https://movantik.com)
NAV_HEADER_REPEATED (https://movantik.com/hcp/)
NAV_HEADER_HEADING_REPEATED_BODY (https://movantik.com/about/)
NAV_HEADER_HEADING_REPEATED_BODY (https://movantik.com/burden-of-oic/)
📝 The Narrative — clean text per page (homepage promise vs. sub-page reality)
HOMEPAGE · THIN (https://movantik.com)
When opioid constipation slows you down, [H1] MOVANTIK gets you moving. [IMG: Number 1 Prescribed Oral Treatment of its kind] [H3] If you’re taking opioids and are constipated, don’t suffer in silence. Find out if MOVANTIK is right for youSame-day relief is possible.Find out howSave with MOVANTIKReferences: 1. MOVANTIK® (naloxegol). Prescribing information. Valinor Pharma, LLC; 2023. 2. Data on file. Prescription data. Valinor Pharma, LLC; 2023.
SUB-PAGE · THIN (https://movantik.com/hcp/)
For patients experiencing constipation from opioids for chronic non-cancer pain [H1] Anticipate OIC.Treat with confidence. [IMG: Number 1 Prescribed Oral Treatment of its kind] Is it possible your patients are suffering silently from OIC?References: 1. MOVANTIK® (naloxegol). Prescribing information. Valinor Pharma, LLC; 2023. 2. Data on file. Prescription data. Valinor Pharma, LLC; 2023.
SUB-PAGE · THIN (https://movantik.com/about/)
About MOVANTIK [H1] Rapid response with MOVANTIK [H2] In adults with chronic non-cancer pain, MOVANTIK 25 mg was shown to be effective for OIC in 2 clinical studies.1,2 In these studies, MOVANTIK worked quickly, often within 6-12 hours of the first dose1 [IMG: MOVANTIK in the AM may lead to Bowel movement in the PM] References: 1. MOVANTIK® (naloxegol). Prescribing information. Valinor Pharma, LLC; 2023. 2. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387-2396.
SUB-PAGE (https://movantik.com/burden-of-oic/)
Burden of OICSuffering from opioid-induced constipation? [H1] You’re not alone.OIC is prevalent—yetundertreated. [H3] Don’t bear the burden of OIC alone – relief can begin with a conversation1,* [IMG: chart] [IMG: chart] *In an analysis of a multinational longitudinal study of 493 patients with chronic non-cancer pain and clinician-identified, patient-confirmed OIC.1†Constipation treatments included OTC laxatives (stool softeners, osmotics, stimulants, salines, and rectal options), prescription laxatives, and behavioral therapies (fiber supplements, increased fluids and exercise, and dietary changes). 29% of patients in the study reported “much benefit” from constipation treatments.1OTC treatment is usually not enough6References: 1. Coyne KS, LoCasale RJ, Datto CJ, Sexton CC, Yeomans K, Tack J. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res. 2014;6:269-281. 2. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35-42. 3. Abramowitz L, Beziaud N, Labreze L. Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med Econ. 2013;16(2):1423-1433. 4. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372-380. 5. Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Clinical Guidelines Committee. Gastroenterology. 2019;156:218-226. 6. Brock C, Olesen SS, Olesen AE, Frøkjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72(14):1847-1865.
This page presents a snapshot of public data from MOVANTIK, captured on May 24, 2026, to show how machine logic reads Semantic Coherence signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to MOVANTIK: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://movantik.com to view the most current version of its content and see directly what this company is about and what it offers.